Autoimmunity

Strategies for the assessment of competences during rheumatology training across Europe: results of a qualitative study
Aurélie Najm, Alessia Alunno, Francisca Sivera, Sofia Ramiro, Catherine Haines

RMD Open Jul 2020, 6 (2) e001183; DOI: 10.1136/rmdopen-2020-001183
Autoantigen TRIM21/Ro52 is expressed on the surface of antigen-presenting cells and its enhanced expression in Sjögren’s syndrome is associated with B cell hyperactivity and type I interferon activity
Maarten R Hillen, Katia Urso, Emma Koppe, Ana Pinheiro Lopes, Sofie L M Blokland, Aridaman Pandit, Tom Slocombe, André van Maurik, Joel A G van Roon, Timothy R D J Radstake

RMD Open Jun 2020, 6 (2) e001184; DOI: 10.1136/rmdopen-2020-001184
Distinct features distinguishing IgG4-related disease from multicentric Castleman's disease
Takanori Sasaki, Mitsuhiro Akiyama, Yuko Kaneko, Takehiko Mori, Hidekata Yasuoka, Katsuya Suzuki, Kunihiro Yamaoka, Shinichiro Okamoto, Tsutomu Takeuchi

RMD Open Jul 2017, 3 (1) e000432; DOI: 10.1136/rmdopen-2017-000432
Automated evaluation of ANA under real-life conditions
Clemens Dario Loock, Karl Egerer, Eugen Feist, Gerd-Rüdiger Burmester

RMD Open Apr 2017, 3 (1) e000409; DOI: 10.1136/rmdopen-2016-000409
Dermatomyositis flare on imiquimod therapy highlights a crucial role of aberrant TLR7 signalling
Alain Meyer, Ghada Alsaleh, Claude Heuschling, Jacques-Eric Gottenberg, Philippe Georgel, Benard Geny, Seiamak Bahram, Jean Sibilia

RMD Open Oct 2016, 2 (2) e000294; DOI: 10.1136/rmdopen-2016-000294
Treatment of systemic sclerosis: is there any hope for the future?
Yannick Allanore, Marco Matucci-Cerinic, Oliver Distler

RMD Open Jul 2016, 2 (2) e000260; DOI: 10.1136/rmdopen-2016-000260
Leucocyte subset-specific type 1 interferon signatures in SLE and other immune-mediated diseases
Shaun M Flint, Vojislav Jovanovic, Boon Wee Teo, Anselm Mak, Julian Thumboo, Eoin F McKinney, James C Lee, Paul MacAry, David M Kemeny, David RW Jayne, Kok Yong Fong, Paul A Lyons, Kenneth GC Smith

RMD Open May 2016, 2 (1) e000183; DOI: 10.1136/rmdopen-2015-000183
Predictive value of autoantibodies from anti-CCP2, anti-MCV and anti-human citrullinated fibrinogen tests, in early rheumatoid arthritis patients with rapid radiographic progression at 1 year: results from the ESPOIR cohort
Yannick Degboé, Arnaud Constantin, Delphine Nigon, Gabriel Tobon, Martin Cornillet, Thierry Schaeverbeke, Gilles Chiocchia, Pascale Nicaise-Roland, Leonor Nogueira, Guy Serre, Alain Cantagrel, Adeline Ruyssen-Witrand

RMD Open Nov 2015, 1 (1) e000180; DOI: 10.1136/rmdopen-2015-000180
Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 study
Michael Schiff, Bernard Combe, Thomas Dörner, Joel M Kremer, Thomas W Huizinga, Melissa Veenhuizen, Anne Gill, Wendy Komocsar, Pierre-Yves Berclaz, Robert Ortmann, Chin Lee

RMD Open Aug 2015, 1 (1) e000037; DOI: 10.1136/rmdopen-2014-000037
For patients with rheumatic disease and hepatitis C infection: the end of interferon
Leonard H Calabrese, Patrice P Cacoub

RMD Open Jan 2015, 1 (1) e000008; DOI: 10.1136/rmdopen-2014-000008

Log in using your username and password

Main menu

Log in using your username and password

You are here

Autoimmunity